Zai Lab Shares Rise on Positive Phase 1 Trial Data for Lung Cancer Treatment

Dow Jones10-23
 
 

Zai Lab shares rose in premarket trading Friday after the company said that it reported positive data from its phase 1 trial evaluating its small cell lung cancer treatment.

Shares rose 7.3% ahead of the morning bell to $23.65.

The biopharmaceutical company said Friday that its experimental drug, zocilurtatug pelitecan, showed high tumor response rates and a favorable safety profile. This was when combined with an immunotherapy treatment in patients receiving initial care for advanced small cell lung cancer.

"The high confirmed response rate, encouraging durability, and well-tolerated safety profile we are seeing with a standard chemotherapy-free regimen are particularly compelling," said President and Head of Global Research and Development Rafael Amado.

The company said that it is preparing to begin a global phase 3 trial of the drug as well as an immuno-oncology regimen to explore other potential combinations.

 
 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment